Jazz Pharmaceuticals (JAZZ) FY2015 results: revenue $1.3 billion, up 13.0% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.3 billion for fiscal 2015, the year ended 31 December 2015, up 13.0% on the year before. Net income was $330 million, up 464.4%, and diluted earnings per share $5.23. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2016.
Revenue
$1.3 billion
+13.0% on the year
FY2009FY2015
Operating margin
38.4%
16.7% a year earlier
FY2009FY2015
Net income
$330 million
+464.4% on the year
FY2009FY2015
Diluted EPS
$5.23
+462.4% on the year
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
1,325
1,173
872
+13.0%
Research and development
135
85.2
41.6
+58.8%
Selling, general and administrative
449
406
304
+10.6%
Operating income
508
196
340
+159.8%
Operating margin
38.4%
16.7%
39.0%
Interest expense
26.5
n/a
n/a
Pre-tax income
436
152
308
+187.6%
Income tax
106
94.2
91.6
+12.9%
Effective tax rate
24.4%
62.2%
29.8%
Net income
330
58.4
216
+464.4%
Net margin
24.9%
5.0%
24.8%
Diluted EPS
$5.23
$0.93
$3.51
+462.4%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
532
408
288
+30.5%
Capital expenditure
36.0
36.3
10.0
-1.1%
Free cash flow
496
371
278
+33.6%
Free cash flow margin
37.4%
31.7%
31.9%
Cash from investing
-2.3
-1,068
-16.3
Cash from financing
-214
711
-23.9
Depreciation and amortisation
9.9
134
82.1
-92.6%
Share-based compensation
91.5
69.6
44.6
+31.5%
Buybacks
61.6
42.2
136
+45.8%
Diluted shares, weighted
63m
63m
62m
+0.7%
Shares outstanding at period end
61m
61m
58m
+1.1%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
1,599
1,371
1,296
+16.6%
Non-controlling interest
0.0
0.1
0.0
Debt
1,188
1,342
550
-11.5%
Other liabilities
546
625
393
-12.8%
Total liabilities and equity
3,333
3,339
2,238
-0.2%
Fixed assets
85.6
58.4
14.2
+46.6%
Goodwill
657
703
450
-6.5%
Intangible assets
1,186
1,437
812
-17.5%
Cash and equivalents
989
684
637
+44.6%
Receivables
210
186
125
+12.5%
Inventory
19.5
30.0
28.7
-35.2%
Other assets
186
240
171
-22.3%
Total assets
3,333
3,339
2,238
-0.2%
10-K for the year ended 31 December 2015, filed 23 February 2016: the filing.